Share
67 Posts.
lightbulb Created with Sketch. 42
clock Created with Sketch. 29/01/25
10:10
Share
Originally posted by seanc:
↑
Agree with you Nashezz, what I’m saying is there is a lot to consider about a small development company like Neuren becoming a BP and JP has stated publicly that becoming a BP is not part of the strategy, I don’t believe we have the capability and capacity to effectively transform, we only have to look at the current delays we are experiencing. Not to mention there are two other indications at ph11 that need focus. Then we have to consider the moral obligation that we have to expedite development. TO by BP is obviously going to happen and as HT eloquently pointed out don’t expect multiple premium’s to be paid. All points to $50 a share as they say we can like it or lump it, personally I’ll like it. GLA
Expand
I think part of the analysis is whether $50 a share is fair, or whether it’s chump change for a drug that is second to none.
(20min delay)